Contrasting AbCellera Biologics (NASDAQ:ABCL) & Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ:ANIK) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Profitability

This table compares Anika Therapeutics and AbCellera Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-1.43%	1.87%	1.39%
AbCellera Biologics	-218.54%	-15.35%	-10.84%

Analyst Recommendations

This is a breakdown of recent recommendations for Anika Therapeutics and AbCellera Biologics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1	1	2	0	2.25
AbCellera Biologics	1	1	7	2	2.91

Anika Therapeutics currently has a consensus price target of $22.00, suggesting a potential upside of 57.71%. AbCellera Biologics has a consensus price target of $16.20, suggesting a potential upside of 35.56%. Given Anika Therapeutics’ higher possible upside, equities research analysts clearly believe Anika Therapeutics is more favorable than AbCellera Biologics.

Institutional & Insider Ownership

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Anika Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.

Earnings & Valuation

This table compares Anika Therapeutics and AbCellera Biologics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82 million	1.66	-$10.88 million	($0.13)	-107.31
AbCellera Biologics	$67.85 million	54.00	-$146.41 million	($0.48)	-24.90

Anika Therapeutics has higher revenue and earnings than AbCellera Biologics. Anika Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

Anika Therapeutics beats AbCellera Biologics on 8 of the 15 factors compared between the two stocks.

About Anika Therapeutics

Anika Therapeutics is a medical technology company focused on orthopedic care and regenerative medicine. Founded in 1992 and headquartered in Bedford, Massachusetts, the company develops products using hyaluronic acid, a substance found naturally in the body and used in treatments for joint and tissue conditions. Its products include Orthovisc and Monovisc, injectable hyaluronic acid treatments for knee osteoarthritis. Anika also offers orthopedic products for areas such as sports medicine, joint preservation, and bone repair, including its Tactoset bone-void filler.

About AbCellera Biologics

AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.